Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133528 | 0.98 | ADRA1A (0.53) | ADRA1AADRA2AADRA1DADRA1BHTR2B | |
| SCHEMBL724530 | 0.98 | ADRA1A (0.53) | ADRA1AADRA2AADRA1DADRA1BHTR2B | |
| SCHEMBL7856564 | 0.98 | ADRA1A (0.53) | ADRA1AADRA2AADRA1DADRA1BHTR2B | |
| Hydrochloric Acid SCHEMBL11394021 | 0.96 | ADRA1A (0.52) | ADRA1AADRA2AADRA1DADRA1BHTR2B | |
| SCHEMBL1494449 | 0.95 | — | — | |
| SCHEMBL196337 | 0.91 | — | — | |
| SCHEMBL16512331 | 0.84 | ADRA1A (0.49) | ADRA1AADRA2AADRA1DADRA1BHTR2B | |
| SCHEMBL1299321 | 0.83 | ADRA1A (0.52) | ADRA1AADRA2AADRA1DADRA1BHTR2B | |
| SCHEMBL2488698 | 0.83 | ADRA1A (0.52) | ADRA1AADRA2AADRA1DADRA1BHTR2B | |
| SCHEMBL4585762 | 0.83 | ADRA1A (0.52) | ADRA1AADRA2AADRA1DADRA1BHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-12-24 | — | — | US | claimed |
| EP-2118077-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-12-24 | — | — | EP | claimed |
| US-20140296186-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2014-10-02 | — | — | US | claimed |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-09-25 | — | — | US | claimed |
| US-20140066428-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-06 | — | — | US | claimed |
| EP-2384328-B1 | 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM INT (DE) | 2013-02-13 | — | — | EP | claimed |
| US-8362055-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-8318790-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-27 | — | — | US | claimed |
| EP-1817295-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2012-11-07 | — | — | EP | claimed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | claimed |
| WO-2007139968-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | claimed |
| WO-2007139967-A2 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | claimed |
| EP-1817295-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corporation (US) | 2007-08-15 | — | — | EP | claimed |
| JP-2007512358-A | — | — | 2007-05-17 | — | — | JP | claimed |
| WO-2006055760-A9 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1685127-A1 | HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES | The University of Connecticut (US) | 2006-08-02 | — | — | EP | claimed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | claimed |
| WO-2006055760-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20050215568-A1 | Substituted oxetanes, method of making, and method of use thereof | UNIVERSITY OF CONNECTICUT, THE | 2005-09-29 | — | — | US | claimed |
| WO-2005051944-A1 | HETEROCYCLYL-SUBSTITUTED OXETANES FOR THE TREATMENT OF PROLIFERATIVE OR INFECTIOUS DISEASES | UNIVERSITY OF CONNECTICUT (US) | 2005-06-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066428-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HTR1A, HTR2C, TPH1 | ADRA1A 26/4885ADRA2A 35/4885ADRA1D 28/4885 |
| US-20050215568-A1 | Substituted oxetanes, method of making, and method of use thereof | PNP, TYMP, DHPS | ADRA1A 3546/4885ADRA2A 3917/4885ADRA1D 3720/4885 |
| US-20140296186-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ADRA1A 3771/4885ADRA2A 4037/4885ADRA1D 4055/4885 |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ADRA1A 3771/4885ADRA2A 4037/4885ADRA1D 4055/4885 |
| US-20140288301-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | ADRA1A 3771/4885ADRA2A 4037/4885ADRA1D 4055/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | ADRA1A 3914/4885ADRA2A 4132/4885ADRA1D 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.